1 Abbott NJ. Blood–brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 2013; 36: 437–449.
2 Pardridge WM. Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain. Front. Aging Neurosci. 2020; 11. doi:10.3389/fnagi.2019.00373.
3 Mills E, Dong X-P, Wang F, Xu H. Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med Chem 2010; 2: 51–64.
4 Abbott NJ, Rönnbäck L, Hansson E. Astrocyte–endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 2006; 7: 41–53.
5 Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13–25.
6 Daneman R, Prat A. The blood–brain barrier. Cold Spring Harb Perspect Biol 2015; 7. doi:10.1101/cshperspect.a020412.
7 Greene C, Hanley N, Campbell M. Claudin-5: gatekeeper of neurological function. Fluids Barriers CNS 2019; 16: 3.
8 Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967; 34: 207–217.
9 Zlokovic B V. The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. Neuron 2008; 57: 178–201.
10 Kevadiya BD, Ottemann BM, Thomas M Ben, Mukadam I, Nigam S, McMillan JE et al. Neurotheranostics as personalized medicines. Adv Drug Deliv Rev 2018. doi:10.1016/j.addr.2018.10.011.
11 Moura RP, Martins C, Pinto S, Sousa F, Sarmento B. Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology. Expert Opin. Drug Deliv. 2019; 16: 271–285.
12 Bhatti UF, Williams AM, Georgoff PE, Alam HB. The ‘Omics’ of Epigenetic Modulation by Valproic Acid Treatment in Traumatic Brain Injury—What We Know and What the Future Holds. Proteomics - Clin. Appl. 2019; 13. doi:10.1002/prca.201900068.
13 Helgudottir SS, Routhe LJ, Burkhart A, Jønsson K, Pedersen IS, Lichota J et al. Epigenetic Regulation of Ferroportin in Primary Cultures of the Rat Blood-Brain Barrier. Mol Neurobiol 2020; 57: 3526–3539.
14 Zuchero YJY, Chen X, Bien-Ly N, Bumbaca D, Tong RK, Gao X et al. Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies. Neuron 2016; 89: 70–82.
15 Long Z, Zeng Q, Wang K, Sharma A, He G. Gender difference in valproic acid-induced neuroprotective effects on APP/PS1 double transgenic mice modeling Alzheimer’s disease. Acta Biochim Biophys Sin (Shanghai) 2016; 48: 930–938.
16 Ibarra M, Vázquez M, Fagiolino P, Derendorf H. Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn 2013; 40: 479–486.
17 Chaliha D, Albrecht M, Vaccarezza M, Takechi R, Lam V, Al-Salami H et al. A Systematic Review of the Valproic-Acid-Induced Rodent Model of Autism. Dev Neurosci 2020; 42: 12–48.
18 Johnsen KB, Bak M, Kempen PJ, Melander F, Burkhart A, Thomsen MS et al. Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles. Theranostics 2018; 8: 3416–3436.
19 Kucharz K, Kristensen K, Johnsen KB, Lund MA, Lønstrup M, Moos T et al. Post-capillary venules are the key locus for transcytosis-mediated brain delivery of therapeutic nanoparticles. Nat Commun 2021; 12. doi:10.1038/S41467-021-24323-1.
20 Thomsen MS, Birkelund S, Burkhart A, Stensballe A, Moos T. Synthesis and deposition of basement membrane proteins by primary brain capillary endothelial cells in a murine model of the blood-brain barrier. J Neurochem 2017; 140: 741–754.
21 Thomsen MS, Humle N, Hede E, Moos T, Burkhart A, Thomsen LB. The blood-brain barrier studied in vitro across species. PLoS One 2021; 16. doi:10.1371/journal.pone.0236770.
22 Perrière N, Demeuse PH, Garcia E, Regina A, Debray M, Andreux JP et al. Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties . J Neurochem 2005; 93: 279–289.
23 Calabria AR, Weidenfeller C, Jones AR, De Vries HE, Shusta E V. Puromycin-purified rat brain microvascular endothelial cell cultures exhibit improved barrier properties in response to glucocorticoid induction. J Neurochem 2006; 97: 922–933.
24 Hill JJ, Haqqani AS, Stanimirovic DB. Proteome of the Luminal Surface of the Blood-Brain Barrier. Proteomes 2021; 10: 45. doi: 10.3390/proteomes9040045.
25 Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012; 9: 676–682.
26 Supek F, Bošnjak M, Škunca N, Šmuc T. REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms. PLoS One 2011; 6: e21800.
27 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
28 Moos T. Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system - Moos - 1996 - Journal of Comparative Neurology - Wiley Online Library. J Comp Neurol 1996; 375: 675–692.
29 Jefferies WA, Brandon MR, Hunt S V., Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature 1984; 312: 162–163.
30 Christian H, Helms C, Kristensen M, Saaby L, Fricker G, Brodin B. Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB). doi:10.1007/164_2020_403.
31 Hwang JY, Aromolaran KA, Zukin RS. The emerging field of epigenetics in neurodegeneration and neuroprotection. Nat. Rev. Neurosci. 2017; 18: 347–361.
32 Bowman GD, Poirier MG. Post-translational modifications of histones that influence nucleosome dynamics. Chem. Rev. 2015; 115: 2274–2295.
33 Ying GY, Jing CH, Li JR, Wu C, Yan F, Chen JY et al. Neuroprotective Effects of Valproic Acid on Blood-Brain Barrier Disruption and Apoptosis-Related Early Brain Injury in Rats Subjected to Subarachnoid Hemorrhage Are Modulated by Heat Shock Protein 70/Matrix Metalloproteinases and Heat Shock Protein 70/AKT Pathways. Neurosurgery 2016; 79: 286–295.
34 Zhao W, Zhao L, Guo Z, Hou Y, Jiang J, Song Y. Valproate Sodium Protects Blood Brain Barrier Integrity in Intracerebral Hemorrhage Mice. Oxid Med Cell Longev 2020; 2020. doi:10.1155/2020/8884320.
35 Wang Z, Leng Y, Tsai LK, Leeds P, Chuang DM. Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 2011; 31: 52–57.
36 Ornoy A, Becker M, Weinstein-Fudim L, Ergaz Z. S-Adenosine Methionine (SAMe) and Valproic Acid (VPA) as Epigenetic Modulators: Special Emphasis on their Interactions Affecting Nervous Tissue during Pregnancy. Int J Mol Sci 2020; 21. doi:10.3390/IJMS21103721.
37 Johnsen KB, Burkhart A, Melander F, Kempen PJ, Vejlebo JB, Siupka P et al. Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci Rep 2017. doi:10.1038/s41598-017-11220-1.
38 Zhang W, Liu QY, Haqqani AS, Leclerc S, Liu Z, Fauteux F, et al. Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human. Fluids Barriers CNS. 2020; 22: 47. doi: 10.1186/s12987-020-00209-0.
39 Crielaard BJ, Lammers T, Rivella S. Targeting iron metabolism in drug discovery and delivery. Nat Publ Gr 2017; 16. doi:10.1038/nrd.2016.248.
40 Drakesmith H, Nemeth E, Ganz T. Ironing out Ferroportin. Cell Metab 2015; 22: 777–787.
41 Gulec S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol 2014; 307. doi:10.1152/AJPGI.00348.2013.
42 Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics. J Neurochem 2016; 139 Suppl 1: 179–197.
43 Silva B, Faustino P. An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim Biophys Acta 2015; 1852: 1347–1359.
44 Duck KA, Connor JR. Iron uptake and transport across physiological barriers. BioMetals 2016 294 2016; 29: 573–591.
45 Helgudottir SS. Expressional prerequisites for targeted drug delivery to the pathological brain. Aalborg University. Faculty of Health. Ph.D.-Series, 2021.
46 Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2006; 2: 406–414.
47 Morgan EH, Moos T. Mechanism and developmental changes in iron transport across the blood-brain barrier. Dev Neurosci 2002; 24: 106–113.
48 Moos T, Oates PS, Morgan EH. Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency. J Comp Neurol 1998; 398: 420–430.
49 Taylor EM, Crowe A, Morgan EH. Transferrin and iron uptake by the brain: effects of altered iron status. J Neurochem 1991; 57: 1584–1592.
50 Moos T, Morgan EH. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. J Neurochem 2001; 79: 119–129.
51 Chiou B, Neal EH, Bowman AB, Lippmann ES, Simpson IA, Connor JR. Endothelial cells are critical regulators of iron transport in a model of the human blood-brain barrier. J Cereb Blood Flow Metab. 2019: 39 :2117-2131. doi: 10.1177/0271678X18783372.
52 Van Gelder W, Huijskes‐Heins MIE, Van Dijk JP, Cleton‐Soeteman MI, Van Eijk HG. Quantification of different transferrin receptor pools in primary cultures of porcine blood-brain barrier endothelial cells. J Neurochem 1995; 64: 2708–2715.
53 Daneman R, Zhou L, Agalliu D, Cahoy JD, Kaushal A, Barres BA. The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS One 2010; 5: e13741.
54 Simpson IA, Carruthers A, Vannucci SJ. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 2007; 27: 1766–1791.
55 Simpson IA, Vannucci SJ, DeJoseph MR, Hawkins RA. Glucose transporter asymmetries in the bovine blood-brain barrier. J Biol Chem 2001; 276: 12725–12729.
56 Xiuli G, Meiyu G, Guanhua D. Glucose transporter 1, distribution in the brain and in neural disorders: its relationship with transport of neuroactive drugs through the blood-brain barrier. Biochem Genet 2005; 43: 175–187.
57 Winkler EA, Nishida Y, Sagare AP, Rege S V., Bell RD, Perlmutter D et al. GLUT1 reductions exacerbate Alzheimer’s disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci 2015; 18: 521–530.
58 Keaney J, Campbell M. The dynamic blood–brain barrier. FEBS J 2015; 282: 4067–4079.
59 Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011; 117: 333–345.
60 Zhang W, Liu QY, Haqqani AS, Leclerc S, Liu Z, Fauteux F et al. Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human. Fluids Barriers CNS 2020; 17: 1–17.